EU Critical Medicines Act finalised after 15 months of negotiation

The European Union's Critical Medicines Act has moved from political declaration to legal text. On 30 June 2026, the Council of the European Union published the consolidated version of the regulation, annexed to a letter addressed to the chair of the European Parliament's public health committee. The publication marks the end of a 15-month legislative sprint that began with the European Commission's proposal in March 2025 and concluded with a marathon trilogue session under the Cyprus presidency in the early hours of 12 May.

From pandemic lesson to legislative framework

The Act is the most concrete expression yet of the 'European Health Union' concept that emerged from the COVID-19 pandemic. When borders closed and global supply chains seized up in early 2020, member states discovered that essential antibiotics, anaesthetics and intensive-care medicines were dependent on a handful of active pharmaceutical ingredient (API) producers in China and India. The Commission's 2020 pharmaceutical strategy flagged the problem; the 2022 shortages of amoxicillin and paracetamol across half the EU turned it into a political imperative.

The regulation establishes a Union list of critical medicines, to be adopted by the Commission through delegated acts on the advice of the European Medicines Agency (EMA). Inclusion criteria cover therapeutic indispensability, severity of the condition treated, and supply vulnerability. Once a medicine is listed, marketing authorisation holders must notify the EMA of any discontinuance or interruption at least six months in advance, or as soon as practicable for unforeseen events. Member states, in turn, must report national stock levels and production capacities for listed medicines every six months.

Stockpiling, joint procurement and the solidarity clause

The Act's operational core lies in its shortage response mechanisms. The EMA will maintain a European shortage monitoring system fed by national competent authorities and industry. When a critical medicine faces a Union-wide shortage, the Commission can activate a joint procurement procedure, similar to the vaccine purchasing mechanism used during the pandemic, but now codified in secondary law with defined triggers and timelines. A solidarity clause obliges member states with surplus stocks to make them available to others facing critical shortfalls, subject to fair compensation and domestic needs.

Strategic stockpiling moves from ad hoc national practice to a coordinated framework. Each member state must maintain a strategic reserve for listed medicines, calibrated to population size and epidemiological risk. The Commission will assess national stockpiling plans every two years and can issue recommendations. The EMA's executive steering group on shortages, upgraded from its current informal status, becomes the operational hub for coordination.

What 'Made in Europe' actually means in the text

The phrase 'Made in Europe' appears in recitals and political declarations but the binding provisions are more surgical. The regulation creates a 'critical medicines manufacturing incentive scheme' that offers three concrete benefits to companies investing in EU-based API or finished-product capacity for listed medicines: accelerated scientific advice and protocol assistance from the EMA; regulatory flexibility on variation procedures for manufacturing site changes; and priority access to relevant EU funding instruments, notably the Strategic Technologies for Europe Platform (STEP) and the EU4Health programme.

Crucially, the Act does not mandate domestic production quotas or 'buy European' clauses. The Parliament's initial position had pushed for a 30% EU-sourcing target for critical APIs; the Council rejected this as incompatible with WTO rules and the single market. The compromise settles on a monitoring obligation: the Commission must report every three years on the geographic concentration of API supply for listed medicines, with a view to proposing further measures if dependency on third countries exceeds defined thresholds.

The Cyprus presidency's 12-hour endgame

The provisional agreement on 12 May followed a negotiating dynamic that mirrored the broader pharmaceutical package. The Parliament, rapporteured by the S&D group's health spokesperson, sought stronger enforcement powers for the EMA, including the ability to impose fines on non-compliant companies. The Council, led by member states with significant generic industries, notably Germany, France and Italy, resisted supranational sanctions, preferring national enforcement under coordinated guidelines. The Cyprus presidency brokered a compromise: the EMA can issue binding recommendations and publish non-compliance notices, but financial penalties remain a national competence.

Another flashpoint was the definition of 'critical'. The Commission's original proposal left the list entirely to delegated acts. The Parliament wanted the list in the regulation itself, subject to co-decision for amendments. The final text adopts a hybrid: an initial list adopted by delegated act within six months of entry into force, with subsequent updates also by delegated act but subject to a strengthened scrutiny procedure allowing the Parliament or Council to object within two months.

Interaction with the wider pharmaceutical reform

The Critical Medicines Act does not exist in isolation. It sits alongside the revised pharmaceutical legislation, the directive and regulation on medicinal products for human use, which were negotiated in parallel but on a slower track. The pharmaceutical reform addresses intellectual property incentives, data exclusivity, and environmental risk assessment; the Critical Medicines Act focuses exclusively on supply security. The two texts cross-reference each other: the critical medicines list feeds into the reform's 'unmet medical need' designation, which carries extended regulatory protection. Conversely, the reform's provisions on supply obligations for all authorised medicines create a baseline that the Critical Medicines Act strengthens for the listed subset.

This layered architecture reflects a deliberate political choice. Rather than reopening the entire pharmaceutical acquis, a process that typically takes years, the Commission opted for a targeted regulation on critical medicines that could move quickly under Article 168 TFEU (public health), while the broader reform proceeds under Article 114 (internal market). The result is a patchwork that industry groups describe as 'regulatory lasagne', but which policymakers defend as pragmatic incrementalism.

Implementation timeline and open questions

The regulation enters into force 20 days after publication in the Official Journal, expected in late July 2026. Most provisions apply 18 months later, giving member states until early 2028 to transpose monitoring obligations, establish national contact points, and align stockpiling plans. The first critical medicines list is due within six months of entry into force, roughly January 2027. The EMA's upgraded steering group must be operational within nine months.

Three implementation questions remain unresolved in the text. First, the definition of 'fair compensation' for the solidarity clause is left to a Commission implementing act, creating scope for divergent national interpretations. Second, the interaction with the EU's foreign direct investment screening regulation is unaddressed: if a non-EU investor acquires a European API plant producing a listed medicine, the Act is silent on whether that triggers a security review. Third, the funding envelope for the manufacturing incentive scheme is not quantified in the regulation; it depends on the mid-term revision of the multiannual financial framework, currently under negotiation for the 2028-2034 period.